Latest Insider Transactions at Eye Point Pharmaceuticals, Inc. (EYPT)
This section provides a real-time view of insider transactions for Eye Point Pharmaceuticals, Inc. (EYPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EyePoint Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EyePoint Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2024
|
Goran Ando |
BUY
Open market or private purchase
|
Direct |
5,000
+27.55%
|
$35,000
$7.95 P/Share
|
|
Aug 20
2024
|
Wendy F Dicicco |
BUY
Open market or private purchase
|
Direct |
2,567
+20.48%
|
$17,969
$7.79 P/Share
|
|
Aug 19
2024
|
Karen L. Zaderej |
BUY
Open market or private purchase
|
Direct |
12,500
+43.1%
|
$87,500
$7.98 P/Share
|
|
Aug 16
2024
|
Nancy Lurker |
BUY
Open market or private purchase
|
Direct |
3,173
+3.15%
|
$22,211
$7.88 P/Share
|
|
Jul 12
2024
|
David R Guyer |
SELL
Open market or private sale
|
Direct |
11,625
-86.27%
|
$116,250
$10.06 P/Share
|
|
Jul 12
2024
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,775
+32.24%
|
$29,325
$3.38 P/Share
|
|
Jul 11
2024
|
Karen L. Zaderej |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+33.33%
|
-
|
|
Jul 10
2024
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,059
-17.49%
|
$64,472
$8.69 P/Share
|
|
Jul 10
2024
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+26.56%
|
-
|
|
Jul 10
2024
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
11,111
+10.52%
|
-
|
|
Jun 23
2024
|
Anthony P Adamis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+33.33%
|
-
|
|
Jun 03
2024
|
David R Guyer |
SELL
Open market or private sale
|
Direct |
11,625
-75.86%
|
$116,250
$10.3 P/Share
|
|
Jun 03
2024
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,775
+26.29%
|
$29,325
$3.38 P/Share
|
|
May 25
2024
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,627
-7.1%
|
$39,897
$11.16 P/Share
|
|
May 25
2024
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+12.8%
|
-
|
|
May 14
2024
|
David R Guyer |
SELL
Open market or private sale
|
Direct |
11,625
-67.69%
|
$139,500
$12.65 P/Share
|
|
May 14
2024
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,775
+23.91%
|
$29,325
$3.38 P/Share
|
|
May 06
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
850,000
+4.88%
|
$10,200,000
$12.03 P/Share
|
|
Apr 18
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
581,765
+3.79%
|
$10,471,770
$18.26 P/Share
|
|
Mar 30
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,546
-10.04%
|
$510,920
$20.67 P/Share
|
|
Mar 30
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,404
+17.32%
|
-
|
|
Feb 27
2024
|
Jay S. Duker President and CEO |
BUY
Bona fide gift
|
Indirect |
2,500
+10.0%
|
-
|
|
Feb 27
2024
|
Jay S. Duker President and CEO |
SELL
Bona fide gift
|
Direct |
2,500
-7.83%
|
-
|
|
Feb 20
2024
|
Jay S. Duker President and CEO |
BUY
Bona fide gift
|
Indirect |
20,000
+50.0%
|
-
|
|
Feb 20
2024
|
Jay S. Duker President and CEO |
SELL
Bona fide gift
|
Direct |
20,000
-38.52%
|
-
|
|
Feb 13
2024
|
Nancy Lurker |
BUY
Bona fide gift
|
Indirect |
74,681
+37.05%
|
-
|
|
Feb 13
2024
|
Nancy Lurker |
SELL
Bona fide gift
|
Direct |
74,681
-47.26%
|
-
|
|
Feb 09
2024
|
Nancy Lurker |
SELL
Payment of exercise price or tax liability
|
Direct |
14,943
-4.42%
|
$418,404
$28.8 P/Share
|
|
Feb 09
2024
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
37,534
+10.3%
|
-
|
|
Feb 09
2024
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,533
-3.24%
|
$98,924
$28.8 P/Share
|
|
Feb 09
2024
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,967
+10.2%
|
-
|
|
Feb 09
2024
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,192
-3.47%
|
$89,376
$28.8 P/Share
|
|
Feb 09
2024
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+10.95%
|
-
|
|
Feb 09
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,656
-3.84%
|
$102,368
$28.8 P/Share
|
|
Feb 09
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,967
+9.78%
|
-
|
|
Feb 09
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,083
-5.53%
|
$142,324
$28.8 P/Share
|
|
Feb 09
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+10.84%
|
-
|
|
Feb 02
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
209
-0.55%
|
$5,852
$28.49 P/Share
|
|
Feb 02
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209
+0.54%
|
$2,299
$11.47 P/Share
|
|
Jan 26
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,325
-22.08%
|
$1,233,125
$25.53 P/Share
|
|
Jan 26
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,325
+17.11%
|
$641,225
$13.05 P/Share
|
|
Jan 26
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
26,017
-22.92%
|
$650,425
$25.36 P/Share
|
|
Jan 26
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,017
+18.61%
|
$208,136
$8.08 P/Share
|
|
Jan 25
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-0.81%
|
$15,000
$25.0 P/Share
|
|
Jan 25
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+0.81%
|
$7,800
$13.02 P/Share
|
|
Jan 25
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
600
-0.78%
|
$15,000
$25.0 P/Share
|
|
Jan 25
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+0.78%
|
$4,800
$8.08 P/Share
|
|
Jan 24
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,300
-12.21%
|
$282,500
$25.01 P/Share
|
|
Jan 24
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,300
+10.88%
|
$90,400
$8.08 P/Share
|
|
Jan 24
2024
|
Nancy Lurker |
SELL
Open market or private sale
|
Direct |
29,956
-18.11%
|
$718,944
$24.98 P/Share
|